Target intelligence / Profile preview

T-cell immunoglobulin and mucin-domain receptor (TIM receptor)

Target
TIM receptor
Molecular classification
Receptor, Immune checkpoint receptor, Immunoglobulin superfamily, Single-pass type I membrane protein
01

Overview

The T-cell immunoglobulin and mucin-domain receptor family (TIM) comprises cell-surface proteins with an N-terminal immunoglobulin-like domain and a mucin-like domain. They regulate immune responses by modulating T cell activity, recognizing phosphatidylserine on apoptotic cells, and serving as immune checkpoints (notably TIM-3). STRUCTURALLY, TIM family members are single-pass transmembrane glycoproteins with a conserved immunoglobulin V (IgV) domain and variable-length mucin domain. Biologically, these proteins participate in immune regulation, tolerance, and immunopathology; for example, TIM-3 is a negative immune regulator implicated in suppressing T cell function in cancer, while TIM-1 functions in allergy, infection, and kidney injury. Multiple therapeutic antibodies targeting TIM receptors, especially TIM-3, are in clinical development as anti-cancer agents via immunomodulation.

Other names
TIM familyT-cell immunoglobulin mucin (TIM) familyTIM-1TIM-2TIM-3TIM-4Hepatitis A virus cellular receptor 1 (HAVCR1; TIM-1)Hepatitis A virus cellular receptor 2 (HAVCR2; TIM-3)Kin of IRM (KIM-1; for TIM-1)
02

Mechanism of action

Immune checkpoint inhibition (antibodies block TIM-3 function to reverse T cell exhaustion and promote anti-tumor immunity); Modulation of T cell responses/inhibition of immunosuppression

03

Biological functions

Immune response regulationImmune checkpoint inhibitionRecognition of apoptotic cells (binds phosphatidylserine)T cell activation or inhibitionCell adhesionAntigen presentationModulation of inflammation
04

Disease associations

CancerAutoimmunityAllergyInflammationInfectionCardiovascular diseaseRenal disease
05

Safety considerations

Risk of immune-related adverse events due to enhanced immune activation (as seen with other checkpoint blockade)Potential exacerbation of autoimmune or inflammatory responses
06

Interacting drugs

Monoclonal antibodies against TIM-3 (clinical development in cancer immunotherapy)

1 more in the full profile.

07

Biomarkers

Surface expression of TIM-3 on T cells as a marker of T cell exhaustion in cancer and chronic infectionTIM-3 levels on T cells in cardiovascular and autoimmune diseases

Beyond the preview

Go deeper on T-cell immunoglobulin and mucin-domain receptor (TIM receptor).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell immunoglobulin and mucin-domain receptor (TIM receptor).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call